| Code | CSB-RA012895MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to LYT-200, targeting LGALS9 (Galectin-9), a β-galactoside-binding lectin that plays critical roles in immune regulation and cellular homeostasis. LGALS9 functions as an immune checkpoint molecule by binding to TIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3) on T cells, inducing apoptosis of Th1 and Th17 cells and promoting immune tolerance. This protein is implicated in various pathological conditions including cancer immune evasion, autoimmune disorders, chronic viral infections, and inflammatory diseases, where its expression levels correlate with disease progression and therapeutic outcomes.
LYT-200 represents a therapeutic antibody candidate developed to modulate LGALS9-mediated immune suppression in the tumor microenvironment. This biosimilar antibody provides researchers with a valuable tool for investigating LGALS9 biology, exploring immune checkpoint mechanisms, studying tumor-immune interactions, and evaluating potential therapeutic strategies in immuno-oncology and autoimmune disease models. It supports preclinical research aimed at understanding galectin-mediated immunoregulation and developing novel immunotherapeutic approaches.
There are currently no reviews for this product.